睿知中国医院研究地图
候选清单

上海海军军医大学

海军军医大学第二附属医院(长征医院)

Changzheng Hospital

在本站收录的 53 种疾病中,这家医院列在其中 18 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

海军军医大学第二附属医院(长征医院)的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma3 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma15 篇牵头论文牵头 1 项开放试验
  3. 胃癌Stomach cancer17 篇牵头论文牵头 1 项开放试验
  4. 脊索瘤Chordoma5 篇牵头论文
  5. 骨肉瘤Osteosarcoma16 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour4 篇牵头论文
  7. 神经母细胞瘤Neuroblastoma0 篇牵头论文
  8. 尤文肉瘤Ewing sarcoma2 篇牵头论文
  9. 多发性骨髓瘤Multiple myeloma26 篇牵头论文牵头 2 项开放试验
  10. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  11. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis1 篇牵头论文
  12. 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文
  13. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis0 篇牵头论文
  14. 白塞病Behçet disease1 篇牵头论文
  15. IgA 肾病IgA nephropathy5 篇牵头论文
  16. 成骨不全症Osteogenesis imperfecta2 篇牵头论文
  17. 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
  18. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文

未列出的收录疾病:鼻咽癌、肝母细胞瘤、视网膜母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

上海有 18 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题分子标志物与基因影像与人工智能手术
论文中的科室影像/核医学科
牵头的论文3
  1. FOXA3: A Novel Tumor Suppressor in Esophageal Squamous Cell Carcinoma.2025The journal of gene medicine
  2. Potential value of CT-based comprehensive nomogram in predicting occult lymph node metastasis of esophageal squamous cell paralaryngeal nerves: a two-center study.2024Journal of translational medicine免费全文
  3. Transcervical inflatable mediastinoscopic esophagectomy versus thoracoscopic esophagectomy for local early- and intermediate-stage esophageal squamous cell carcinoma: A propensity score-matched analysis.2022Journal of surgical oncology免费全文
中文论文(未计入)1
  1. [Research on the application of combined inflatable mediastinoscopy with laparoscopy guided by the concept of "reduced field and port" in esophageal squamous cell carcinoma].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
PubMed 以外找到的论文(未计入)10
  1. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  2. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  3. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  4. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  5. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  6. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  7. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  8. Additional file 2 of Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma2022Figshare数据集
  9. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  10. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.1%。

牵头论文
15
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 2220232024: 7720242025: 112025

上海有 15 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
    分期
    早期I期
    开始
    2024-10
    登记号
    NCT06418659

    年龄 18 岁 至 未注明(登记的条件)

    牵头:海军军医大学第二附属医院(长征医院)上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物局部治疗(消融、TACE、HAIC)
论文中的科室消化/肝病科影像/核医学科病理/检验科
牵头的论文15
  1. Effectiveness of Nursing Care Intervention Among Patients With Hepatocellular Carcinoma Undergoing Surgery: A Systematic Review and Meta-Analysis.2025International journal of nursing practice
  2. DDR1 is a Novel Biomarker and Potential Therapeutic Target for the Combination Treatment of Liver Hepatocellular Carcinoma.2024Cancer control : journal of the Moffitt Cancer Center免费全文
  3. Tripartite motif 8 promotes the progression of hepatocellular carcinoma via mediating ubiquitination of HNF1α.2024Cell death & disease免费全文
  4. Profiling of aberrant sialylated N-glycans in hepatocellular carcinoma by liquid chromatography mass spectrometry.2024Clinica chimica acta; international journal of clinical chemistry
  5. Combined RNAi of CTTN and FGF2 Modulates Cell Migration, Invasion and G1/S Transition of Hepatocellular Carcinoma through Ras/ERK Signaling Pathway.2024Current cancer drug targets
  6. Dichotomous roles of ADAR1 in liver hepatocellular carcinoma and kidney renal cell carcinoma: Unraveling the complex tumor microenvironment and prognostic significance.2024International immunopharmacology
  7. Abrogating K458 acetylation enhances hepatocyte nuclear factor 4α (HNF4α)-induced differentiation therapy for hepatocellular carcinoma.2024Journal of digestive diseases
  8. Cathepsin V is correlated with the prognosis and tumor microenvironment in liver cancer.2024Molecular carcinogenesis
  9. Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B.2023Alimentary pharmacology & therapeutics
  10. Role of miRNA-99a-5p in Modulating the Function of Hepatocellular Carcinoma Cells: Bioinformatics Analysis and In Vitro Assay.2023Current cancer drug targets
  11. Influence of Three-Dimensional Visual Reconstruction Technology Combined with Virtual Surgical Planning of CTA Images on Precise Resection of Liver Cancer in Hepatobiliary Surgery.2022Computational and mathematical methods in medicine免费全文
  12. Operator radiation dose during trans-hepatic arterial chemoembolization: different patients' positions via transradial or transfemoral access.2022Diagnostic and interventional radiology (Ankara, Turkey)RCT免费全文
  13. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.2022Frontiers in immunology免费全文
  14. Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy.2021European journal of pharmacology
  15. Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report.2021The Journal of international medical research免费全文
中文论文(未计入)1
  1. [Advances of TRIM superfamily proteins in chronic liver disease and hepatocellular carcinoma].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients正在招募NCT06418659牵头方早期I期2024-10 启动
  2. A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma已完成NCT06092112牵头方早期I期2023-10 启动
  3. T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients已终止NCT00057382研究中心II/III期2003-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 17 篇,占 0.2%。

牵头论文
17
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 3320222023: 4420232024: 0020242025: 552025

上海有 18 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer
    分期
    II期
    开始
    2026-07
    登记号
    NCT07621484

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:海军军医大学第二附属医院(长征医院)上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期免疫与靶向药物手术
论文中的科室肿瘤内科消化/肝病科
牵头的论文17
  1. Organoid-based single cell sequencing revealed the lineage evolution during docetaxel treatment in gastric cancer.2025Cancer letters
  2. Brucea javanica Seed Oil Emulsion and Shengmai Injections Improve Peripheral Microcirculation in Treatment of Gastric Cancer.2025Chinese journal of integrative medicine
  3. Effect and Mechanism of 6-Gingerol against Precancerous Lesions of Gastric Cancer Based on Network Pharmacology and In Vitro Experiment.2025Combinatorial chemistry & high throughput screening
  4. Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer.2025Frontiers in immunology免费全文
  5. Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial.2025Nature communications免费全文
  6. Tumor- and metastasis-promoting roles of miR-488 inhibition via HULC enhancement and EZH2-mediated p53 repression in gastric cancer.2023Cell biology and toxicology
  7. PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients.2023Clinical genetics
  8. Research progress on the immune microenvironment and immunotherapy in gastric cancer.2023Frontiers in immunology免费全文
  9. Xiaotan Sanjie decoction normalizes tumor permissive microenvironment in gastric cancer (Review).2023Oncology reports
  10. Long non-coding RNA ncRuPAR regulates gastric cancer cell proliferation and apoptosis via phosphoinositide 3-kinase/protein kinase B signaling.2022International journal of medical sciences免费全文
  11. Folate Decorated Multifunctional Biodegradable Nanoparticles for Gastric Carcinoma Active Targeting Theranostics.2022International journal of nanomedicine免费全文
  12. Ziyin Huatan Recipe, a Chinese herbal compound, inhibits migration and invasion of gastric cancer by upregulating RUNX3 expression.2022Journal of integrative medicine
  13. UBE3C promotes proliferation and inhibits apoptosis by activating the β-catenin signaling via degradation of AXIN1 in gastric cancer.2021Carcinogenesis
  14. Simultaneous laparoscopic subtotal gastrectomy (Billroth II) and total colectomy with ileorectal anastomosis for synchronous gastric and multifocal colon cancer - a video vignette.2021Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  15. The effects of gastric cancer interstitial fluid on tumors based on traditional Chinese medicine 'phlegm' theory and the investigation on the mechanism through microRNA-21 regulation.2021Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  16. Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis.2021Technology in cancer research & treatment免费全文
  17. HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma.2021The oncologist免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer正在招募NCT07621484牵头方II期2026-07 启动
  2. Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)状态不明NCT04278222牵头方II期2020-02 启动
  3. EGFR Monoclonal Antibody for Advanced Gastric Cancer状态不明NCT04136600牵头方II期2019-07 启动
  4. Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC状态不明NCT04638959研究中心2019-09 启动
  5. XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)已完成NCT03399110研究中心III期2018-01 启动
  6. A Study of the Efficacy and Safety of PerOx Quench on the Prevention of Oxaliplatin Treatment Induced Neuropathy已终止NCT02560740研究中心不分期2016-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 4.8%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025

上海有 15 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科
牵头的论文5
  1. Targeting the tumor immune microenvironment in chordoma: From mechanistic insights to therapeutic breakthroughs.2026Biochimica et biophysica acta. Reviews on cancer
  2. Gross Total Resection of the Entire Cervical Spine Tumor: A Technical Note on Surgical Planning and Design of a Novel 3D-Printed Vertebral Prosthesis for Reconstruction from Skull Base to Thoracic Vertebra.2026World neurosurgery
  3. Ubiquitin-independent pathway regulates the RIT1-MAPK pathway in chordoma progression.2025Cell death & disease
  4. A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib.2024Journal of cancer research and clinical oncology
  5. Early Major Complications After Radical Resection of Primary C2-Involved Upper Cervical Chordoma Through the Combined Anterior Retropharyngeal-Posterior Approach: Incidence and Risk Factors.2021World neurosurgery
早期论文(2016–2020 年)8
  1. Shifting from targeted therapies to personalised treatment in chordoma - Authors' reply.2020The Lancet. Oncology
  2. Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study.2020The Lancet. Oncology
  3. Application of Individualized 3D-Printed Artificial Vertebral Body for Cervicothoracic Reconstruction in a Six-Level Recurrent Chordoma.2020Turkish neurosurgery
  4. Recurrence or neurological loss? Resection mode selection for patients with large sacral chordoma: an analysis of prognostic factors and quality of life.2019Acta neurochirurgica
  5. Prognostic significance of pretreatment plasma D-dimer levels in patients with spinal chordoma: a retrospective cohort study.2019European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  6. Surgical Consideration for Adolescents and Young Adults With Cervical Chordoma.2017Spine
  7. Epidemiological characteristics of primary spinal osseous tumors in Eastern China.2017World journal of surgical oncology
  8. Spine extra-osseous chordoma mimicking neurogenic tumors: report of three cases and review of the literatures.2016World journal of surgical oncology

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 16 篇,占 0.7%。

牵头论文
16
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 4420232024: 4420242025: 552025

上海有 60 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文16
  1. Lactate Activates the HCAR1/β-Arrestin2/PP2A Signaling Axis to Mediate STAT1/2 Dephosphorylation and Drive Osteosarcoma Progression.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  2. Bone-Targeted Fluoropeptide Nanoparticle Inhibits NF-κB Signaling to Treat Osteosarcoma and Tumor-Induced Bone Destruction.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  3. Decoding Osteosarcoma's Lactylation Gene Expression: Insights Into Prognosis, Immune Dynamics, and Treatment.2025Analytical cellular pathology (Amsterdam)
  4. Targeting AKT as a promising strategy for SOX2-positive, chemoresistant osteosarcoma.2025Bone research
  5. The malignant dialogue between cancer-associated fibroblasts and osteosarcoma cells: microenvironment-mediated drug resistance and therapeutic targets.2025Frontiers in immunology
  6. IL-11-Engineered Macrophage Membrane-Coated Reactive Oxygen Species-Responsive Nanoparticles for Targeted Delivery of Doxorubicin to Osteosarcoma.2024ACS applied materials & interfaces
  7. KDELR1 regulates chondrosarcoma drug resistance and malignant behavior through Intergrin-Hippo-YAP1 axis.2024Cell death & disease
  8. New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma.2024Frontiers in immunology
  9. Small Nuclear Ribonucleoprotein Polypeptides B and B1 Promote Osteosarcoma Progression via Activating the Ataxia-Telangiectasia Mutated Signaling Pathway through Ribonucleotide Reductase Subunit M2.2024The American journal of pathology
  10. Deubiquitinase USP13 regulates glycolytic reprogramming and progression in osteosarcoma by stabilizing METTL3/m6A/ATG5 axis.2023International journal of biological sciences
  11. BARX1 promotes osteosarcoma cell proliferation and invasion by regulating HSPA6 expression.2023Journal of orthopaedic surgery and research
  12. Prognostic factors of sarcomas occurring in bone and joint: A SEER based study.2023Medicine
  13. Study on the effect of artificial joint replacement for osteosarcoma.2023Medicine
  14. AMTB, a TRPM8 antagonist, suppresses growth and metastasis of osteosarcoma through repressing the TGFβ signaling pathway.2022Cell death & disease
  15. TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling.2022Redox biology
  16. Identifying the Risk Factors and Estimating the Prognosis in Patients with Pelvis and Spine Ewing Sarcoma: A Population-Based Study.2021Spine
早期论文(2016–2020 年)25
  1. Secondary aneurysmal bone cyst of the spine: Clinicopathological features, surgical modalities and outcomes.2020Clinical neurology and neurosurgery
  2. The CD24+ cell subset promotes invasion and metastasis in human osteosarcoma.2020EBioMedicine
  3. Metformin induces cell cycle arrest, apoptosis and autophagy through ROS/JNK signaling pathway in human osteosarcoma.2020International journal of biological sciences
  4. Long intergenic non-coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo.2020Journal of clinical laboratory analysis
  5. Hypoxia-Inducible Factor 1A Upregulates HMGN5 by Increasing the Expression of GATA1 and Plays a Role in Osteosarcoma Metastasis.2019BioMed research international
  6. The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.2019Biochemical and biophysical research communications
  7. MicroRNA-221 promotes cisplatin resistance in osteosarcoma cells by targeting PPP2R2A.2019Bioscience reports
  8. EWS-FLI1-mediated tenascin-C expression promotes tumour progression by targeting MALAT1 through integrin α5β1-mediated YAP activation in Ewing sarcoma.2019British journal of cancer
  9. GREM1 overexpression inhibits proliferation, migration and angiogenesis of osteosarcoma.2019Experimental cell research
  10. Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy.2019International journal of nanomedicine
  11. Prognostic Factors for Patients With Undifferentiated High Grade Pleomorphic Sarcoma of the Spine.2019Spine
  12. Establishment of a Nomogram-Based Model for Predicting the Prognostic Value of Inflammatory Biomarkers and Preoperative D-Dimer Level in Spinal Ewing's Sarcoma Family Tumors: A Retrospective Study of 83 Patients.2019World neurosurgery
  13. Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/β-catenin signaling.2018Biochemical and biophysical research communications
  14. Heat shock transcription factor 1 promotes the proliferation, migration and invasion of osteosarcoma cells.2017Cell proliferation
  15. A support vector machine classifier for the prediction of osteosarcoma metastasis with high accuracy.2017International journal of molecular medicine
  16. Does rarity mean imparity? Biological characteristics of osteosarcoma cells originating from the spine.2017Journal of cancer research and clinical oncology
  17. Factors affecting survival outcomes of patients with non-metastatic Ewing's sarcoma family tumors in the spine: a retrospective analysis of 63 patients in a single center.2017Journal of neuro-oncology
  18. MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy.2017Scientific reports
  19. Parthenolide Induces Reactive Oxygen Species-Mediated Autophagic Cell Death in Human Osteosarcoma Cells.2016Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  20. Promotion of tumour proliferation, migration and invasion by miR-92b in targeting RECK in osteosarcoma.2016Clinical science (London, England : 1979)
  21. TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma.2016Journal of cancer research and clinical oncology
  22. Effects of RNA interference-mediated knockdown of livin and survivin using monomethoxypolyethylene glycol-chitosan nanoparticles in MG-63 osteosarcoma cells.2016Molecular medicine reports
  23. miR-146b-5p promotes invasion and metastasis contributing to chemoresistance in osteosarcoma by targeting zinc and ring finger 3.2016Oncology reports
  24. The predictive potential and oncogenic effects of HOXC8 expression on osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  25. P50-associated COX-2 extragenic RNA (PACER) overexpression promotes proliferation and metastasis of osteosarcoma cells by activating COX-2 gene.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 2220242025: 002025

上海有 21 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 34 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. PEG-Ceramide Nanomicelles Induce Autophagy and Degrade Tau Proteins in N2a Cells.2020International journal of nanomedicine

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

上海有 15 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 26 篇,占 1.6%。

牵头论文
26
2021–2025 年
牵头试验
14
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 7720222023: 3320232024: 4420242025: 992025

上海有 16 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
    分期
    早期I期
    开始
    2024-06
    登记号
    NCT06407947

    年龄 18 岁 至 未注明(登记的条件)

    牵头:海军军医大学第二附属医院(长征医院)上海

  2. 正在招募
    a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
    分期
    早期I期
    开始
    2024-12
    登记号
    NCT06718270

    年龄 18 岁 至 未注明(登记的条件)

    牵头:海军军医大学第二附属医院(长征医院)上海

  3. 正在招募
    KPD Consolidation After ASCT in NDMM Patients
    分期
    II/III期
    开始
    2025-03
    登记号
    NCT06879379

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学人民医院;另有 1 家列出的医院为研究中心上海、北京

  4. 正在招募
    To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
    分期
    早期I期
    开始
    2023-07
    登记号
    NCT06045091

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

  5. 正在招募
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    分期
    IV期
    开始
    2022-03
    登记号
    NCT05201781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南京、广州、成都、杭州、福州、西安

  6. 正在招募
    Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
    分期
    II期
    开始
    2022-07
    登记号
    NCT05594797

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、温州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与耐药诊断、微小残留病与危险分层联合用药
论文中的科室病理/检验科
牵头的论文26
  1. Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTAN2025Annals of hematologyRCT免费全文
  2. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.2025Annals of hematologyRCT免费全文
  3. Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients.2025BMC medical genomics免费全文
  4. Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1.2025Cancer免费全文
  5. DEK facilitates bortezomib resistance of multiple myeloma by modulating ferroptosis.2025Clinical and experimental medicine免费全文
  6. Prognostic significance of hematological parameters and albumin in BCMA-targeted CAR-T therapy for multiple myeloma.2025Frontiers in immunology免费全文
  7. Extracellular Ubiquitin Drives M2 Macrophage Polarization in Multiple Myeloma Through JAK1/STAT3-mediated Transcriptional Activation of CXCR4.2025Journal of cellular biochemistry
  8. CALR regulates the proliferation and drug sensitivity of multiple myeloma cells through the BCL2 signaling pathway.2025Molecular biology reports
  9. GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial.2025The Lancet. Haematology
  10. Interference with PLA2G16 promotes cell cycle arrest and apoptosis and inhibits the reprogramming of glucose metabolism in multiple myeloma cells by modulating the Hippo/YAP signaling pathway.2024Anti-cancer drugs免费全文
  11. Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.2024Clinical and experimental immunology
  12. A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma.2024Clinical cancer research : an official journal of the American Association for Cancer Research免费全文
  13. B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma.2024JAMA oncology免费全文
  14. Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma.2023Blood cancer journal免费全文
  15. Identification and validation of a cellular senescence-related lncRNA signature for prognostic prediction in patients with multiple myeloma.2023Cell cycle (Georgetown, Tex.)免费全文
  16. Sensitive quantitative IgD assay increases progression-free survival prediction accuracy in IgD plasma cell myeloma.2023Leukemia
  17. Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.2022American journal of hematology
  18. CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status.2022American journal of hematology
  19. Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.2022BMC cancer免费全文
  20. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.2022BMC medicine免费全文
  21. Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.2022Clinical and translational medicine免费全文
  22. Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients.2022Journal of thrombosis and thrombolysis
  23. CircRNAs: novel therapeutic targets in multiple myeloma.2022Molecular biology reports
  24. Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma.2021Haematologica免费全文
  25. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.2021International journal of hematology
  26. Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN).2021Leukemia免费全文
中文论文(未计入)6
  1. [BCMA chimeric antigen receptor T cells therapy re-treatment of a patient with recurrent/refractory IgD multiple myeloma: A case report and literature review].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  2. [The efficacy and safety analysis of pomalidomide in the treatment of relapsed/refractory multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  3. [Interpretation of diagnosis of multiple myeloma in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].2022Zhonghua nei ke za zhi
  4. [Analysis of clinical characteristics and prognosis of non-secretory multiple myeloma].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  5. [A case-control study of multiple myeloma patients with central nervous system involvement].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  6. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)36
  1. Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma正在招募NCT06407947牵头方早期I期2024-06 启动
  2. a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia正在招募NCT06718270牵头方早期I期2024-12 启动
  3. Study of CT071 Injection in RRMM or PPCL进行中,不再招募NCT05838131牵头方早期I期2023-04 启动
  4. Study of FasT CAR-T GC012F Injection NDMM Patients状态不明NCT05840107牵头方早期I期2023-05 启动
  5. BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma已完成NCT05376345牵头方I期2022-09 启动
  6. Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma状态不明NCT05412329牵头方I期2022-06 启动
  7. BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma状态不明NCT04617704牵头方早期I期2021-12 启动
  8. Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients状态不明NCT04935580牵头方I/II期2021-06 启动
  9. BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma状态不明NCT04236011牵头方早期I期2020-01 启动
  10. Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma状态不明NCT04122092牵头方2019-10 启动
  11. A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma已完成NCT01852799牵头方II期2012-12 启动
  12. Selinexor in Combination With Immunomodulator (Thalidomide/Pomalidomide/Lenalidomide)in RRMM状态不明NCT04941937牵头方(推断)II期2022-01 启动
  13. A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma状态不明NCT04601935牵头方(推断)I期2020-10 启动
  14. Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma状态不明NCT01249690牵头方(推断)IV期2010-06 启动
  15. KPD Consolidation After ASCT in NDMM Patients正在招募NCT06879379研究中心II/III期2025-03 启动
  16. To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL正在招募NCT06045091研究中心早期I期2023-07 启动
  17. Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM正在招募NCT05594797研究中心II期2022-07 启动
  18. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel正在招募NCT05201781研究中心IV期2022-03 启动
  19. To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM进行中,不再招募NCT05302648研究中心早期I期2022-02 启动
  20. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  21. A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT04557098研究中心II期2020-09 启动
  22. BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma状态不明NCT03943472研究中心早期I期2019-07 启动
  23. A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已终止NCT03758417研究中心II期2019-01 启动
  24. Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma状态不明NCT04003168研究中心I期2019-07 启动
  25. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)已完成NCT03748953研究中心III期2019-01 启动
  26. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03860038研究中心II期2019-01 启动
  27. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma已完成NCT03944057研究中心II期2019-09 启动
  28. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  29. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  30. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma已完成NCT03029234研究中心III期2017-03 启动
  31. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动
  32. Ixazomib Rollover Study已完成NCT02924272研究中心II期2016-12 启动
  33. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)已完成NCT02312258研究中心III期2015-04 启动
  34. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma已完成NCT01818752研究中心III期2013-07 启动
  35. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year已完成NCT02348528研究中心II期2012-09 启动
  36. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma已完成NCT01593410研究中心II期2010-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

上海有 2 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

上海有 9 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

上海有 34 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年没有牵头肌萎缩侧索硬化症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 17 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Clinical diagnosis and management of cervical spondylotic amyotrophy].2017Zhonghua yi xue za zhi

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

上海有 15 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.7%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025

上海有 26 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.0%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

上海有 6 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录
牵头的论文2
  1. Dysfunction of Caveolae-Mediated Endocytic TβRI Degradation Results in Hypersensitivity of TGF-β/Smad Signaling in Osteogenesis Imperfecta.2023Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  2. Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta.2021BioMed research international
早期论文(2016–2020 年)3
  1. Efficacy of Bisphosphonates on Bone Mineral Density and Fracture Rate in Patients With Osteogenesis Imperfecta: A Systematic Review and Meta-analysis.2016American journal of therapeutics
  2. Response to Comment on Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta.2016Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  3. Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta.2016Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

上海有 17 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

上海有 9 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

海军军医大学第二附属医院(长征医院)

Changzheng Hospital

上海

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Shanghai Changzheng Hospital; Second Affiliated Hospital of Naval Medical University; Changzheng Hospital of Naval Medicine University; Changzheng Hospital of the Navy Medical University; Zhabei Branch of Changzheng Hospital; Changzheng Hospital of Naval Medical University; Second Military Medical University/Changzheng Hospital; ChangZheng Hospital

提出更正下载数据